VETOQUINOL Corporate brochure 2010 (year 2009)

12 RESEARCH AND DEVELOPMENT ALWAYS AT THE FOREF With nearly 8% of revenues spent on R & D, Vétoquinol places innovation among its top strategic priorities. The Group’s ongoing aim is to anticipate the needs of veterinarians, owners and breeders so as to serve them better and thereby increase its market share. In 2009, Vétoquinol spent 19.5 million euros on R & D, which employs around one hundred researchers spread across three sites: a main centre in France, a pharmaceutical development unit in Canada and a team of around ten people in Poland. The Group’s strategic priority is to launch innovative products, which, together with external growth, are one of the two levers that allow Vétoquinol to grow faster than the market. TARGETED RESEARCH IN THREE AREAS OF EXPERTISE The aim of the R & D Department is to respond ever more effectively to the needs of veterinarians, owners and breeders, while anticipating changes in regulation. Research focuses on targeted therapeutical areas, in line with Vétoquinol’s strategy, JULY Z IS FOR ZENTONIL ® Launched by Vétoquinol in fifteen countries, Zentonil ® Plus and Zentonil ® Advanced use a new patented technique based on the micro-encapsulation of S-Adenosyl methionine (SAMe), a molecule that enables the synthesis of glutathione, among other processes. Both these innovative products enrich the Zentonil ® brand, which is the market leader in hepatoprotectives for cats and dogs. Zentonil ® Plus and Zentonil ® Advanced are presently the only two products on the market offering SAMe in the form of palatable breakable tablets for greater ease of administration. OUTSTANDING EVENTS